185 related articles for article (PubMed ID: 29787422)
1. Activity of Pembrolizumab in Recurrent Cervical Cancer: Case Series and Review of Published Data.
Kranawetter M; Röhrich S; Müllauer L; Obermair H; Reinthaller A; Grimm C; Sturdza A; Köstler WJ; Polterauer S
Int J Gynecol Cancer; 2018 Jul; 28(6):1196-1202. PubMed ID: 29787422
[TBL] [Abstract][Full Text] [Related]
2. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study.
Hsu C; Lee SH; Ejadi S; Even C; Cohen RB; Le Tourneau C; Mehnert JM; Algazi A; van Brummelen EMJ; Saraf S; Thanigaimani P; Cheng JD; Hansen AR
J Clin Oncol; 2017 Dec; 35(36):4050-4056. PubMed ID: 28837405
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study.
Chung HC; Ros W; Delord JP; Perets R; Italiano A; Shapira-Frommer R; Manzuk L; Piha-Paul SA; Xu L; Zeigenfuss S; Pruitt SK; Leary A
J Clin Oncol; 2019 Jun; 37(17):1470-1478. PubMed ID: 30943124
[TBL] [Abstract][Full Text] [Related]
4. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.
Chow LQM; Haddad R; Gupta S; Mahipal A; Mehra R; Tahara M; Berger R; Eder JP; Burtness B; Lee SH; Keam B; Kang H; Muro K; Weiss J; Geva R; Lin CC; Chung HC; Meister A; Dolled-Filhart M; Pathiraja K; Cheng JD; Seiwert TY
J Clin Oncol; 2016 Nov; 34(32):3838-3845. PubMed ID: 27646946
[TBL] [Abstract][Full Text] [Related]
5. Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma.
Doi T; Piha-Paul SA; Jalal SI; Saraf S; Lunceford J; Koshiji M; Bennouna J
J Clin Oncol; 2018 Jan; 36(1):61-67. PubMed ID: 29116900
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial.
Frenel JS; Le Tourneau C; O'Neil B; Ott PA; Piha-Paul SA; Gomez-Roca C; van Brummelen EMJ; Rugo HS; Thomas S; Saraf S; Rangwala R; Varga A
J Clin Oncol; 2017 Dec; 35(36):4035-4041. PubMed ID: 29095678
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028.
Varga A; Piha-Paul S; Ott PA; Mehnert JM; Berton-Rigaud D; Morosky A; Yang P; Ruman J; Matei D
Gynecol Oncol; 2019 Feb; 152(2):243-250. PubMed ID: 30522700
[TBL] [Abstract][Full Text] [Related]
8. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma.
O'Neil BH; Wallmark JM; Lorente D; Elez E; Raimbourg J; Gomez-Roca C; Ejadi S; Piha-Paul SA; Stein MN; Abdul Razak AR; Dotti K; Santoro A; Cohen RB; Gould M; Saraf S; Stein K; Han SW
PLoS One; 2017; 12(12):e0189848. PubMed ID: 29284010
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab for the treatment of cervical cancer.
Marret G; Borcoman E; Le Tourneau C
Expert Opin Biol Ther; 2019 Sep; 19(9):871-877. PubMed ID: 31322926
[No Abstract] [Full Text] [Related]
10. Treatment with pembrolizumab in programmed death ligand 1-positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE-028 trial.
Reardon DA; Kim TM; Frenel JS; Simonelli M; Lopez J; Subramaniam DS; Siu LL; Wang H; Krishnan S; Stein K; Massard C
Cancer; 2021 May; 127(10):1620-1629. PubMed ID: 33496357
[TBL] [Abstract][Full Text] [Related]
11. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer.
Mehnert JM; Varga A; Brose MS; Aggarwal RR; Lin CC; Prawira A; de Braud F; Tamura K; Doi T; Piha-Paul SA; Gilbert J; Saraf S; Thanigaimani P; Cheng JD; Keam B
BMC Cancer; 2019 Mar; 19(1):196. PubMed ID: 30832606
[TBL] [Abstract][Full Text] [Related]
12. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial.
Carlino MS; Long GV; Schadendorf D; Robert C; Ribas A; Richtig E; Nyakas M; Caglevic C; Tarhini A; Blank C; Hoeller C; Bar-Sela G; Barrow C; Wolter P; Zhou H; Emancipator K; Jensen EH; Ebbinghaus S; Ibrahim N; Daud A
Eur J Cancer; 2018 Sep; 101():236-243. PubMed ID: 30096704
[TBL] [Abstract][Full Text] [Related]
13. Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002).
Santin AD; Deng W; Frumovitz M; Buza N; Bellone S; Huh W; Khleif S; Lankes HA; Ratner ES; O'Cearbhaill RE; Jazaeri AA; Birrer M
Gynecol Oncol; 2020 Apr; 157(1):161-166. PubMed ID: 31924334
[TBL] [Abstract][Full Text] [Related]
14. Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study.
Ott PA; Bang YJ; Berton-Rigaud D; Elez E; Pishvaian MJ; Rugo HS; Puzanov I; Mehnert JM; Aung KL; Lopez J; Carrigan M; Saraf S; Chen M; Soria JC
J Clin Oncol; 2017 Aug; 35(22):2535-2541. PubMed ID: 28489510
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study.
Ott PA; Elez E; Hiret S; Kim DW; Morosky A; Saraf S; Piperdi B; Mehnert JM
J Clin Oncol; 2017 Dec; 35(34):3823-3829. PubMed ID: 28813164
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab for advanced cervical cancer: safety and efficacy.
De Felice F; Giudice E; Bolomini G; Distefano MG; Scambia G; Fagotti A; Marchetti C
Expert Rev Anticancer Ther; 2021 Feb; 21(2):221-228. PubMed ID: 33183120
[No Abstract] [Full Text] [Related]
17. Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract.
Frumovitz M; Westin SN; Salvo G; Zarifa A; Xu M; Yap TA; Rodon AJ; Karp DD; Abonofal A; Jazaeri AA; Naing A
Gynecol Oncol; 2020 Sep; 158(3):570-575. PubMed ID: 32534809
[TBL] [Abstract][Full Text] [Related]
18. Balstilimab and other immunotherapy for recurrent and metastatic cervical cancer.
Bose CK
Med Oncol; 2022 Jan; 39(4):47. PubMed ID: 35092506
[TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab in Recurrent Squamous Cell Carcinoma of the Vulva: Case Report and Review of the Literature.
Shields LBE; Gordinier ME
Gynecol Obstet Invest; 2019; 84(1):94-98. PubMed ID: 30016784
[TBL] [Abstract][Full Text] [Related]
20. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
Seiwert TY; Burtness B; Mehra R; Weiss J; Berger R; Eder JP; Heath K; McClanahan T; Lunceford J; Gause C; Cheng JD; Chow LQ
Lancet Oncol; 2016 Jul; 17(7):956-965. PubMed ID: 27247226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
